Literature DB >> 15238481

Hospitals battling outbreaks of C. difficile.

Laura Eggertson, Barbara Sibbald.   

Abstract

Entities:  

Mesh：

Year:  2004        PMID： 15238481      PMCID： PMC437667          DOI： 10.1503/cmaj.1040979

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  18 in total

1.  Clostridium difficile infection in hospitals: a brewing storm.

Authors:  Louis Valiquette; Donald E Low; Jacques Pépin; Allison McGeer
Journal:  CMAJ       Date:  2004-07-06       Impact factor: 8.262

2.  First, the bad news...

Authors: 
Journal:  CMAJ       Date:  2004-07-06       Impact factor: 8.262

3.  Informing the public.

Authors:  Joseph Erban
Journal:  CMAJ       Date:  2004-08-17       Impact factor: 8.262

4.  Clostridium difficile colitis: a marker for ischemic colitis?

Authors:  Richard Fiddian-Green
Journal:  CMAJ       Date:  2004-11-23       Impact factor: 8.262

5.  Protecting against Clostridium difficile illness.

Authors:  Erica Weir; Ken Flegel
Journal:  CMAJ       Date:  2005-04-26       Impact factor: 8.262

6.  Physicians and advocacy.

Authors: 
Journal:  CMAJ       Date:  2005-05-24       Impact factor: 8.262

7.  Editorial autonomy of CMAJ.

Authors:  Jerome P Kassirer; Frank Davidoff; Kathryn O'Hara; Donald A Redelmeier
Journal:  CMAJ       Date:  2006-02-28       Impact factor: 8.262

8.  Effect of a fermented milk combining Lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial.

Authors:  M Beausoleil; N Fortier; S Guénette; A L'ecuyer; M Savoie; M Franco; J Lachaine; K Weiss
Journal:  Can J Gastroenterol       Date:  2007-11       Impact factor: 3.522

9.  Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production.

Authors:  Michelle Merrigan; Anilrudh Venugopal; Michael Mallozzi; Bryan Roxas; V K Viswanathan; Stuart Johnson; Dale N Gerding; Gayatri Vedantam
Journal:  J Bacteriol       Date:  2010-07-30       Impact factor: 3.490

10.  A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial.

Authors:  Jennifer Peppe; Andrew Porzio; David M Davidson
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.